Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas. Show more

1751 River Run, Fort Worth, TX, 76107, United States

https://actuatetherapeutics.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

59.04M

52 Wk Range

$2.05 - $11.99

Previous Close

$2.74

Open

$2.80

Volume

99,715

Day Range

$2.43 - $2.94

Enterprise Value

65.59M

Cash

13.16M

Avg Qtr Burn

-3.736M

Insider Ownership

16.24%

Institutional Own.

55.40%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Elraglusib Details Advanced Salivary Gland Carcinoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Elraglusib + gemcitabine/nab-paclitaxel (GnP) Details 1L metastatic pancreatic ductal adenocarcinoma (mPDAC)	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Elraglusib (GSK-3β Inhibitor) Details Relapsed/Refractory Neuroblastoma	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Elraglusib (GSK-3β Inhibitor) Details Relapsed/Refractory Ewing Sarcoma	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Oral Elraglusib (GSK-3β Inhibitor) Details Advanced Cancers Including Refractory Metastatic Melanoma	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.